<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Virology, epidemiology, and pathogenesis of parvovirus B19 infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Virology, epidemiology, and pathogenesis of parvovirus B19 infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Virology, epidemiology, and pathogenesis of parvovirus B19 infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeanne A Jordan, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Angela M Caliendo, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          Parvoviridae
         </em>
         family contains two subfamilies: parvoviruses (
         <em>
          Parvovirinae
         </em>
         ), which infect mammals and birds, and densoviruses (
         <em>
          Densovirinae
         </em>
         ), which infect arthropods. The
         <em>
          Parvovirinae
         </em>
         subfamily has been subdivided into eight genera, of which five include human pathogens:
         <em>
          Erythroparvovirus
         </em>
         (B19),
         <em>
          Dependoparvovirus
         </em>
         (adeno-associated viruses),
         <em>
          Protoparvovirus
         </em>
         (human bufavirus),
         <em>
          Bocaparvovirus
         </em>
         (Human bocaviruses), and
         <em>
          Tetraparvovirus
         </em>
         (Human parvovirus 4) along with
         <em>
          Aveparvovirus
         </em>
         ,
         <em>
          Copiparvovirus
         </em>
         , and
         <em>
          Amdoparvovirus
         </em>
         [
         <a href="#rid1">
          1
         </a>
         ]. The focus here will be limited to
         <em>
          Erythroparvovirus
         </em>
         genera in the family
         <em>
          Parvoviridae
         </em>
         , and mainly to human parvovirus B19 (B19 prototype strain); only brief coverage will be given to the less common genotype 2 (prototype strain: LaLi) and genotype 3 (prototype strain: V9) genera within this subfamily [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Unless otherwise specified, parvovirus B19 will be the strain referred to when describing epidemiology and transmission, which are discussed in this topic. The spectrum of disease manifestations, diagnosis, treatment, and prevention of parvovirus B19 are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8330.html" rel="external">
          "Treatment and prevention of parvovirus B19 infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1295525544">
         <span class="h1">
          VIROLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H848079925">
         <span class="h2">
          Classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are three genotypes within the
         <em>
          Erythroparvovirus
         </em>
         genus. Parvovirus B19 is the predominant parvovirus pathogen in humans and the prototype genotype 1 strain. Genotype 2 is comprised of A6 and LaLi, while genotype 3 includes V9 and V9-related isolates [
         <a href="#rid3">
          3-6
         </a>
         ]. Genotypes 1 and 2 are typically found in western countries (eg, United States and Europe), while genotype 3 circulates primarily in Africa and South America [
         <a href="#rid6">
          6,7
         </a>
         ] but has been encountered in Europe and Asia. Compared with genotype 1, much less has been published on the transmission and epidemiology of genotype 2 and genotype 3. The nucleotide sequence differs among the three genotypes by 13 to 14 percent [
         <a href="#rid5">
          5,8
         </a>
         ]. Not surprisingly, the divergence at the amino acid level among the three genotypes is significantly less than that seen at the nucleotide level.
        </p>
        <p class="headingAnchor" id="H848079931">
         <span class="h2">
          Viral structure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parvovirus B19 is a small (26 nm), nonenveloped, single-stranded DNA (5.6-kb) virus. It is among the smallest of the DNA animal viruses. The linear genome encodes the following proteins:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two viral capsid proteins: a minor structural protein VP1 (781 amino acids [aa], 84 kDa) and a major structural protein VP2 (554 aa, 58 kDa). These are encoded by overlapping reading frames and are expressed during productive infection. The smaller VP2 protein constitutes 95 percent of the capsid while the larger VP1 protein makes up only 5 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Three nonstructural proteins: a large nonstructural protein, NS1 (671 aa, 78 kDa), and two smaller nonstructural proteins (7.5 kDa and 11 kDa) [
         <a href="#rid9">
          9,10
         </a>
         ]. The major nonstructural protein NS1 is a DNA-binding protein with helicase, nicking, and ATPase activity and is essential for viral DNA replication. NS1 is cytotoxic and induces cellular apoptosis in both permissive and nonpermissive cell types [
         <a href="#rid11">
          11,12
         </a>
         ]. The inflammatory response associated with B19 infection is the result of NS1 transactivation of such pro-inflammatory cytokines as tumor necrosis factor (TNF)-alpha, IL-6, and p21 [
         <a href="#rid13">
          13-15
         </a>
         ]. The NS1 protein is also responsible for inducing cell cycle arrest in erythroid progenitor cells at the G2 phase [
         <a href="#rid10">
          10
         </a>
         ]. Like NS1, the 11 kDa nonstructural protein induces apoptosis as a result of parvovirus B19 infection [
         <a href="#rid16">
          16
         </a>
         ] and enhances viral replication [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H848079987">
         <span class="h2">
          Cellular tropism
         </span>
         <span class="headingEndMark">
          —
         </span>
         One of the hallmarks of Erythroparvoviruses is their extremely limited host range. The only known host for parvovirus B19 is humans [
         <a href="#rid18">
          18
         </a>
         ]. Productive infections occur only in CD36 human erythroid progenitor cells. To date, erythroid precursor cells of the colony and burst forming units (E-CFU and E-BFU) are the only cells known to support a fully productive infection with parvovirus B19 [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The observed tropism of parvovirus is most likely due to the distribution of its cellular receptor, P blood group antigen, also known as globoside, which is found in high concentrations on red blood cells and their precursors [
         <a href="#rid20">
          20
         </a>
         ]. Rare individuals who lack P antigen are resistant to infection with parvovirus [
         <a href="#rid21">
          21
         </a>
         ]. In a well-defined lipid bilayer model, parvovirus B19 viral-like capsids interacted with globoside, suggesting a potential role of globoside as a receptor for B19 [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         P antigen is also found to a lesser extent on other cell types, including endothelial cells, cardiomyocytes, megakaryocytes, and placental trophoblast cells [
         <a href="#rid23">
          23,24
         </a>
         ]. The globoside-containing, nonerythroid cell types that become infected with parvovirus B19 produce little, if any, infectious virus. However, these nonproductive infections may contribute to disease through the expression of nonstructural (NS1) protein, which can induce cellular apoptosis in both permissive and nonpermissive cells [
         <a href="#rid9">
          9,11,12,19
         </a>
         ].
        </p>
        <p>
         Although P antigen may be necessary for infection, it is not sufficient. Some cell lines that are positive for P antigen fail to bind, whereas other cell lines have an ability to bind parvovirus B19 despite lack of P antigen [
         <a href="#rid25">
          25
         </a>
         ]. Two coreceptors have been proposed for virus entry into target cells. These include integrin alpha 5 beta 1 [
         <a href="#rid26">
          26
         </a>
         ] and Ku80, an autoantigen [
         <a href="#rid27">
          27
         </a>
         ]. After the initial B19 VP2-associated binding to the globoside receptor, structural changes occur within the viral capsid, exposing VP1u protein onto the surface of the capsid. This higher affinity binding to an as yet unknown receptor results in internalization of the viral particle into the cytoplasm of the cell [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H848080524">
         <span class="h2">
          Viral life cycle
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following cell entry, viral DNA replication, RNA transcription, protein translation, and virus capsid assembly all occur in the cell's nucleus. In high concentrations, virus particles can be visualized in the nucleus by electron microscopy (EM). Upon viral maturation, parvovirus B19 causes cell lysis. The cytopathic effect induced during B19 infection can be seen in the form of giant pronormoblasts located in the patient's bone marrow [
         <a href="#rid29">
          29
         </a>
         ]. These cells contain large eosinophilic nuclear inclusions, cytoplasmic vacuolization, and marginated chromatin.
        </p>
        <p>
         Active or reactivated infection may be distinguished from latent infection by differential microRNA (miRNA) expression profiles. This was illustrated in a study of 60 patients with serologic evidence of parvovirus B19 infection who underwent endomyocardial biopsy for nonacute cardiomyopathy [
         <a href="#rid30">
          30
         </a>
         ]. There were 29 miRNAs that were differentially regulated in cardiac tissue between the 15 patients with and the 45 patients without transcriptionally active parvovirus B19 infection (as manifest by detectable parvovirus B19 mRNA in biopsy specimens). These miRNAs coded for differentially expressed mRNAs from the cardiomyopathy and inflammatory response related pathways, including TNFα, RORC, and Cox1.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H848080847">
         <span class="h2">
          Geographic and temporal distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parvovirus B19 infection occurs worldwide. Cases can be sporadic or can occur in clustered outbreaks. Where reportable, communities have documented not only a seasonality to parvovirus B19 infections, but also cycles of local epidemics with case numbers that can peak every 4 to 10 years [
         <a href="#rid31">
          31-33
         </a>
         ]. In the United States, parvovirus B19 infection occurs more frequently between late winter and early summer.
        </p>
        <p>
         Parvovirus B19 genotype 1 is the predominant genotype circulating worldwide, while genotypes 2 and 3 are found much less frequently. Genotype 2 is primarily detected in Europe and Africa, while genotype 3 is detected mainly in Africa, South America, and to some extent in Asia [
         <a href="#rid6">
          6
         </a>
         ]. Genotypes 2 and 3 are also identified among patients with underlying immune deficiencies.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parvovirus B19 infection is common throughout the world. The percentage of people with measurable levels of parvovirus B19-specific IgG increases with increasing age, with most individuals becoming infected during their school years. During school outbreaks, 25 to 50 percent of students and 20 percent or more of susceptible staff may become infected. Between 50 to 80 percent of adults have measurable parvovirus B19-specific IgG antibodies [
         <a href="#rid34">
          34,35
         </a>
         ]. Seroprevalence depends on the assay type used to measure B19-specific IgG antibodies [
         <a href="#rid36">
          36-38
         </a>
         ].
        </p>
        <p>
         When considering women as a separate group, approximately half of women of child-bearing age and approximately 30 to 40 percent of pregnant women lack measurable IgG to parvovirus B19 and are therefore presumed to be susceptible to B19 infection, which then places their fetus at risk. (See
         <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">
          "Parvovirus B19 infection during pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Transmission and risk factors for infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are three documented modes of transmitting parvovirus B19:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory transmission
         </strong>
         – Parvovirus B19 is easily transmitted from person to person via the respiratory route, which is the most common way an individual acquires this virus. Although parvovirus B19 infection is not primarily associated with respiratory symptoms, parvovirus B19 has consistently been found in respiratory secretions during the viremic phase of infection [
         <a href="#rid39">
          39-41
         </a>
         ]. It can thus be transmitted through close person-to-person contact, fomites, and respiratory secretions and/or saliva [
         <a href="#rid41">
          41
         </a>
         ]. Due to their nonenveloped virion capsid, parvoviruses, including B19, are stable in the environment, making fomites a likely and important source for transmission.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Young children are the main source of respiratory-acquired parvovirus B19. Individuals at highest risk for acquiring the virus include household contacts of infected individuals, daycare workers, and those in a crowded environment. Household transmission appears to be especially efficient, with about 50 percent of susceptible subjects becoming infected after household exposure to an individual with erythema infectiosum or transient aplastic crisis [
         <a href="#rid39">
          39,40
         </a>
         ]. Among daycare workers working with children, rates of parvovirus B19 seroconversion are also higher than in the general population [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many infections occur with no clearly defined exposure, especially during community outbreaks. During one outbreak, the risk of infection without a clearly defined exposure was 6 percent [
         <a href="#rid43">
          43
         </a>
         ]. Other studies found that 0.5 to 1.5 percent of women without a specific exposure or defined community outbreak became infected during one year or during their pregnancy [
         <a href="#rid36">
          36,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nosocomial transmission of parvovirus B19 can occur from patient-to-patient, patient-to-staff, staff-to-patient, and staff-to-staff. In one study, for example, transmission from two patients with transient aplastic crisis was noted in 36 and 42 percent of susceptible contacts [
         <a href="#rid45">
          45
         </a>
         ]. In several other reports, no source for infection was identified, but transmission apparently occurred between staff and patients [
         <a href="#rid46">
          46,47
         </a>
         ]. However, other series did not find nosocomial transmission [
         <a href="#rid48">
          48,49
         </a>
         ]; in these studies, the rate of infection in exposed or at-risk staff was similar to unexposed staff and/or community controls. It is therefore likely that many cases of presumed nosocomial transmission may actually represent infection acquired in the community during outbreaks of B19.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vertical transmission
         </strong>
         – A susceptible woman who becomes infected with parvovirus B19 during her pregnancy can transmit the virus to the fetus [
         <a href="#rid50">
          50
         </a>
         ]. The risk of a poor outcome for the fetus is greatest when the congenital infection occurs within the first 20 weeks of gestation. (See
         <a class="medical medical_review" href="/z/d/html/8281.html" rel="external">
          "Parvovirus B19 infection during pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematogenous transmission
         </strong>
         – Parvovirus B19 can be transmitted through blood or blood products that contain the virus [
         <a href="#rid51">
          51-56
         </a>
         ]. Infected blood donors may be asymptomatic yet have very high circulating viral levels, up to 10
         <sup>
          12
         </sup>
         viral particles/mL blood [
         <a href="#rid57">
          57,58
         </a>
         ]. Individuals requiring regular infusions of blood product(s) that are made from large plasma pools are at greatest risk for acquiring the virus compared to those individuals receiving single units [
         <a href="#rid53">
          53,54
         </a>
         ]. Both its small size and its lack of a lipid envelope make parvovirus B19 extremely difficult to inactivate or remove from blood products. In one study, 87 percent of 38 blood product and plasma pools were positive for parvovirus B19 DNA by a PCR assay despite a variety of purification and inactivation procedures [
         <a href="#rid54">
          54
         </a>
         ]. Several nanofiltration methods have been developed to help remove virus particles during the manufacture of plasma derivatives or hemoglobin solution to prevent transmission of viruses. In one study, using a 20 nm Viresolve nanofilter (Millipore, USA), up to 6.43 10E5 units/mL of parvovirus B19 was successfully removed from human plasma, and the viral DNA was undetectable using a real-time PCR assay [
         <a href="#rid59">
          59
         </a>
         ]. Other studies have shown that nanofiltration can decrease parvovirus B19 viral load by more than 6 log10 [
         <a href="#rid60">
          60-62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In 2009, the United States Food and Drug Administration (FDA) published guidance governing parvovirus B19 contamination of pooled plasma or blood products. B19 DNA levels within pooled plasma used for manufacturing blood products must not exceed 10
         <sup>
          4
         </sup>
         international units/mL [
         <a href="#rid63">
          63
         </a>
         ]. This regulation was based on the observations in healthy volunteers that suggest that acute parvovirus B19 infection can be acquired from administration of blood components that contain greater than 10
         <sup>
          7
         </sup>
         genome equivalents/mL of viral DNA [
         <a href="#rid64">
          64-66
         </a>
         ]. In contrast, patients receiving less than 10
         <sup>
          6
         </sup>
         genome equivalents/mL have not shown evidence of virus transmission. The presence of neutralizing activity in all these pools may help to explain the lack of infectivity with exposure to lower viral loads [
         <a href="#rid51">
          51,64,67
         </a>
         ]. Additionally, because nucleic acid amplification testing (NAAT) can detect both intact parvovirus B19 genomes and fragments of degraded DNA, it is important to be cautious in interpreting NAAT data from filtered blood products [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In contrast to parvovirus B19 infections, infections with the emerging human parvovirus 4 (PARV4) are most frequently detected in people who inject drugs. PARV4 was first discovered in an injection drug user who was co-infected with hepatitis B virus [
         <a href="#rid70">
          70
         </a>
         ]. Infection with PARV4 is strongly associated with bloodborne viruses like HBV, HIV, and HCV [
         <a href="#rid71">
          71,72
         </a>
         ]. PARV4 has furthermore been found as a contaminant of plasma pools used in the manufacturing of blood products [
         <a href="#rid70">
          70,73
         </a>
         ], which helps to explain the higher rates of seropositivity to PARV4 in hemophiliacs compared with their nonhemophiliac siblings and supports the predominant parenteral transmission route of this virus [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         Parvovirus B19 has also been detected in urine, but urine has not yet been shown to be involved in transmission of the virus [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1295526221">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parvovirus B19 is directly cytotoxic to colony-forming units (CFU-E) and burst-forming units (BFU-E) of the erythroid series [
         <a href="#rid39">
          39,76
         </a>
         ]. The virus replicates in erythroid progenitor cells (late erythroid cell precursors and burst-forming erythroid progenitors) of the bone marrow and blood leading to their destruction and inhibition of erythropoiesis. During an acute infection, this results in a significant drop in hematocrit. In healthy individuals, red blood cell (RBC) production returns in 10 to 14 days with little anemia. However, in individuals with an increased RBC turnover, even a limited cessation of RBC production can lead to a clinically significant drop in hemoglobin and transient aplastic crisis (TAC). (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Infection in immunocompetent hosts'
         </a>
         .)
        </p>
        <p>
         Parvovirus B19-specific IgM antibodies to both VP1 and VP2 proteins develop soon after infection, can be detected at days 10 through 12, and can persist for up to five months; specific IgG antibodies to the viral capsid proteins are detectable about 15 days 15 days postinfection and persist long term. The role of the humoral immune system in control of parvovirus B19 appears dominant; development of a robust antibody response corresponds to virus clearance and subsequent protection from disease. Importantly, neutralizing antibodies to the unique 227 amino acids at the N-terminus of VP1 (VP1u) are required for an effective immune response [
         <a href="#rid77">
          77,78
         </a>
         ]. Detectable anti-NS1 IgG has been suggested to be associated with persistent infection [
         <a href="#rid79">
          79
         </a>
         ]. In patients unable to control parvovirus B19 infection because of immunosuppression or immunodeficiency, continued lysis of RBC precursors leads to prolonged cessation of RBC production and the development of a severe, chronic pure red cell aplasia and anemia. (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Chronic infection in immunosuppressed hosts'
         </a>
         .)
        </p>
        <p>
         Although the pathogenesis of rash and arthropathy associated with parvovirus B19 infection is not clear, both symptoms generally coincide with measurable serum antibody production and are thus presumed to be at least partially immune mediated. The role of serum antibodies in rash development is also suggested by the appearance of rash after
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         administration to immunodeficient patients with chronic infection [
         <a href="#rid80">
          80
         </a>
         ]. Antigen-antibody immune complexes have been detected during acute infection and are proposed to participate in the pathogenesis of the disease [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Direct viral effects may also be involved in the pathogenesis of these symptoms. Parvovirus B19 DNA and antigen have been detected in a skin biopsy specimen from a patient with erythema infectiosum, suggesting that direct infection of epidermal cells may also contribute to rash development [
         <a href="#rid81">
          81
         </a>
         ]. Studies of individuals presenting with acute parvovirus B19 arthritis have documented parvovirus B19 DNA in joint fluid specimens, but not within specific cells [
         <a href="#rid82">
          82
         </a>
         ]. Thus, it is not yet clear whether viral DNA represents direct infection of the synovial tissue or systemic viremia with seeding of the joint space. It is possible that virus remains in lymphocytes, macrophages, and follicular dendritic cells for longer periods, as has recently been suggested to occur in patients with rheumatoid arthritis [
         <a href="#rid83">
          83
         </a>
         ]. Viral presence in these cells may contribute to the pathogenesis of the disease process. After infection, the B19 DNA genome can persist in solid tissues for life. It is not yet known which cell type(s) harbor parvovirus B19 or what the mechanism is for persistent infection [
         <a href="#rid84">
          84-86
         </a>
         ]. Congenital immunodeficiencies and immunosuppressive therapies increase one's risk of developing a persistent infection due to the person's inability to produce sufficient neutralizing antibodies to B19. For example,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         therapy given to lymphoma patients, which inhibits the production of B cells, is associated with B19 persistence, since production of neutralizing antibodies are necessary to clear this infection [
         <a href="#rid62">
          62
         </a>
         ]. This can make it difficult when interpreting positive B19 DNA nucleic acid amplification test (NAAT) results from solid tissues.
        </p>
        <p>
         Parvovirus B19 infection also elicits a Th-1 type cytokine response. This inflammatory cell-mediated immune response includes the production of tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-2, and/or IL-6 [
         <a href="#rid87">
          87-90
         </a>
         ]. A strong CD8 cell response has also been described [
         <a href="#rid91">
          91
         </a>
         ]. A striking CD8 cell response was maintained and eventually increased over several months after the resolution of illness. The importance of cellular immunity is also suggested by clinical reports of remission of parvovirus B19-induced anemia after initiation of antiretroviral therapy in patients with advanced HIV disease.
        </p>
        <p class="headingAnchor" id="H13908416">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Virology –
         </strong>
         Parvovirus B19 is a small, single-stranded DNA virus that infects and replicates in erythroid progenitor cells of the bone marrow and blood, leading to inhibition of erythropoiesis. The observed tropism of parvovirus is most likely due to the distribution of its cellular receptor, P blood group antigen, globoside, which is found in high concentrations on red blood cells and their precursors. In addition, coreceptors have been shown to participate in viral binding and entry into cells. (See
         <a class="local">
          'Virology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology –
         </strong>
         Parvovirus B19 infection occurs worldwide as sporadic cases or within clustered outbreaks and is highly prevalent. Between 50 and 80 percent of adults have evidence of parvovirus B19-specific IgG antibodies, suggesting prior infection. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transmission and risk factors for infection –
         </strong>
         Parvovirus B19 is most commonly transmitted via the respiratory route. Close contact and sharing of personal items expose susceptible individuals to the respiratory secretions and saliva of infected individuals. Parvovirus B19 is also transmitted vertically, from mother to child, and hematogenously. This latter route includes receipt of blood products, as it is difficult to inactivate or remove this small, nonenveloped virus from blood products. (See
         <a class="local">
          'Transmission and risk factors for infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis –
         </strong>
         The direct cytotoxic effect of parvovirus B19 on colony- and burst-forming units of the erythroid series mediates the drop in hemoglobin and anemia that occurs during infection. Development of a robust antibody response corresponds to virus clearance and subsequent protection from disease. Antibody development also coincides with the development of rash and joint symptoms, which are thus thought to be at least partially immune mediated. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Mietzsch M, Pénzes JJ, Agbandje-McKenna M. Twenty-Five Years of Structural Parvovirology. Viruses 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KE. Variants of B19. Dev Biol (Basel) 2004; 118:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen QT, Sifer C, Schneider V, et al. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37:2483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen QT, Wong S, Heegaard ED, Brown KE. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002; 301:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76:9124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain A, Kant R. Genotypes of erythrovirus B19, their geographical distribution &amp; circulation in cases with various clinical manifestations. Indian J Med Res 2018; 147:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsyan A, Szmaragd C, Allain JP, Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol 2007; 88:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norja P, Eis-Hübinger AM, Söderlund-Venermo M, et al. Rapid sequence change and geographical spread of human parvovirus B19: comparison of B19 virus evolution in acute and persistent infections. J Virol 2008; 82:6427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozawa K, Ayub J, Kajigaya S, et al. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988; 62:2884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu P, Zhou Z, Xiong M, et al. Parvovirus B19 NS1 protein induces cell cycle arrest at G2-phase by activating the ATR-CDC25C-CDK1 pathway. PLoS Pathog 2017; 13:e1006266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moffatt S, Yaegashi N, Tada K, et al. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72:3018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan JA, Butchko AR. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody. Placenta 2002; 23:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moffatt S, Tanaka N, Tada K, et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996; 70:8485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fu Y, Ishii KK, Munakata Y, et al. Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 2002; 76:5395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakashima A, Morita E, Saito S, Sugamura K. Human Parvovirus B19 nonstructural protein transactivates the p21/WAF1 through Sp1. Virology 2004; 329:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AY, Zhang EY, Guan W, et al. The small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells. Blood 2010; 115:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganaie SS, Chen AY, Huang C, et al. RNA Binding Protein RBM38 Regulates Expression of the 11-Kilodalton Protein of Parvovirus B19, Which Facilitates Viral DNA Replication. J Virol 2018; 92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. Proc Natl Acad Sci U S A 2004; 101:11628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortimer PP, Humphries RK, Moore JG, et al. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 1983; 302:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasir W, Nilsson J, Olofsson S, et al. Parvovirus B19 VLP recognizes globoside in supported lipid bilayers. Virology 2014; 456-457:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan JA, DeLoia JA. Globoside expression within the human placenta. Placenta 1999; 20:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rouger P, Gane P, Salmon C. Tissue distribution of H, Lewis and P antigens as shown by a panel of 18 monoclonal antibodies. Rev Fr Transfus Immunohematol 1987; 30:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 2001; 75:4110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 2003; 102:3927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munakata Y, Saito-Ito T, Kumura-Ishii K, et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005; 106:3449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bönsch C, Zuercher C, Lieby P, et al. The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization. J Virol 2010; 84:11737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mende M, Sockel K. Parvovirus B19 Infection. N Engl J Med 2018; 379:2361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kühl U, Rohde M, Lassner D, et al. miRNA as activity markers in Parvo B19 associated heart disease. Herz 2012; 37:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naides SJ. Erythema infectiosum (fifth disease) occurrence in Iowa. Am J Public Health 1988; 78:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeant GR, Serjeant BE, Thomas PW, et al. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993; 341:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamashita K, Matsunaga Y, Taylor-Wiedeman J, Yamazaki S. A significant age shift of the human parvovirus B19 antibody prevalence among young adults in Japan observed in a decade. Jpn J Med Sci Biol 1992; 45:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerr S, O'Keeffe G, Kilty C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999; 57:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch WC, Adler SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989; 8:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson LJ, Tsou C, Parker RA, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986; 24:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Röhrer C, Gärtner B, Sauerbrei A, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008; 136:1564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chorba T, Coccia P, Holman RC, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986; 154:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plummer FA, Hammond GW, Forward K, et al. An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med 1985; 313:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero Starke K, Kofahl M, Freiberg A, et al. Are Daycare Workers at a Higher Risk of Parvovirus B19 Infection? A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2019; 16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartter ML, Farley TA, Rosengren S, et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991; 163:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gay NJ, Hesketh LM, Cohen BJ, et al. Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy? Commun Dis Rep CDR Rev 1994; 4:R104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell LM, Naides SJ, Stoffman P, et al. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989; 321:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison J, Jones CE. Human parvovirus B19 infection in healthcare workers. Occup Med (Lond) 1995; 45:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seng C, Watkins P, Morse D, et al. Parvovirus B19 outbreak on an adult ward. Epidemiol Infect 1994; 113:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell SF, Török TJ, Thorp JA, et al. Parvovirus B19 infection in hospital workers: community or hospital acquisition? J Infect Dis 1995; 172:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray SM, Erdman DD, Berschling JD, et al. Nosocomial exposure to parvovirus B19: low risk of transmission to healthcare workers. Infect Control Hosp Epidemiol 1997; 18:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998; 75:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McOmish F, Yap PL, Jordan A, et al. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993; 31:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortimer PP, Luban NL, Kelleher JF, Cohen BJ. Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet 1983; 2:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoto Y, Kudoh T, Haseyama K, et al. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995; 91:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleinman SH, Glynn SA, Lee TH, et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007; 47:1756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musiani M, Zerbini M, Gentilomi G, et al. Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis 1995; 172:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh DJ, Lee YL, Kang JW, et al. [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus]. Korean J Lab Med 2010; 30:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe H, Sugawara H, Hirayama J, et al. Removal of parvovirus B19 from hemoglobin solution by nanofiltration. Artif Cells Blood Substit Immobil Biotechnol 2000; 28:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenderman AH, ter Hart HG, Prins-de Nijs IM, et al. Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step. Biologicals 2012; 40:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ideno S, Takahashi K, Yusa K, Sakai K. Quantitative PCR evaluation of parvovirus B19 removal via nanofiltration. J Virol Methods 2020; 275:113755.
          </a>
         </li>
         <li class="breakAll">
          Guidance for Industry. Nucleic Acid Testing (NAT) to Reduce the Possible Risk of Human Parvovirus B19 Transmission by Plasma-Derived Products. US HHS FDA CBER, July 2009.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weimer T, Streichert S, Watson C, Gröner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001; 41:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleinman SH, Glynn SA, Lee TH, et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009; 114:3677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hourfar MK, Mayr-Wohlfart U, Themann A, et al. Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion 2011; 51:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsujikawa M, Ohkubo Y, Masuda M, et al. Caution in evaluation of removal of virus by filtration: Misinterpretation due to detection of viral genome fragments by PCR. J Virol Methods 2011; 178:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molenaar-de Backer MW, Russcher A, Kroes AC, et al. Detection of parvovirus B19 DNA in blood: Viruses or DNA remnants? J Clin Virol 2016; 84:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005; 79:8230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manning A, Willey SJ, Bell JE, Simmonds P. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J Infect Dis 2007; 195:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthews PC, Sharp C, Simmonds P, Klenerman P. Human parvovirus 4 'PARV4' remains elusive despite a decade of study. F1000Res 2017; 6:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider B, Fryer JF, Oldenburg J, et al. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia 2008; 14:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp CP, Lail A, Donfield S, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis 2009; 200:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen LS, Madsen TV, Barfod T. Persistent erythrovirus B19 urinary tract infection in an HIV-positive patient. Clin Microbiol Infect 2001; 7:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson S, Momoeda M, Kawase M, et al. Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology 1995; 206:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Poblotzki A, Hemauer A, Gigler A, et al. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis 1995; 172:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz TF, Wiersbitzky S, Pambor M. Case report: detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum. J Med Virol 1994; 43:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95:8227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nikkari S, Roivainen A, Hannonen P, et al. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 1995; 54:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landry ML. Parvovirus B19. Microbiol Spectr 2016; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norja P, Hokynar K, Aaltonen LM, et al. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A 2006; 103:7450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skuja S, Vilmane A, Svirskis S, et al. Evidence of Human Parvovirus B19 Infection in the Post-Mortem Brain Tissue of the Elderly. Viruses 2018; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan JA, Huff D, DeLoia JA. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol 2001; 8:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lower FE, Menon S, Sanchez JA. Association of parvovirus B19 with plasma cell-rich myocardial infiltrates after heart transplantation. J Heart Lung Transplant 2001; 20:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Poblotzki A, Gerdes C, Reischl U, et al. Lymphoproliferative responses after infection with human parvovirus B19. J Virol 1996; 70:7327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner AD, Goronzy JJ, Matteson EL, Weyand CM. Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc 1995; 70:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norbeck O, Isa A, Pöhlmann C, et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005; 79:12117.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8274 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31010002" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Twenty-Five Years of Structural Parvovirology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15645675" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Variants of B19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10405389" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Novel human erythrovirus associated with transient aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12359439" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Identification and characterization of a second novel human erythrovirus variant, A6.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12186896" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genetic diversity within human erythroviruses: identification of three genotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29923512" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Genotypes of erythrovirus B19, their geographical distribution&amp;circulation in cases with various clinical manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17251559" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18417586" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Rapid sequence change and geographical spread of human parvovirus B19: comparison of B19 virus evolution in acute and persistent infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2969055" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28264028" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Parvovirus B19 NS1 protein induces cell cycle arrest at G2-phase by activating the ATR-CDC25C-CDK1 pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9525624" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12175970" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970971" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11991968" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15518826" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Human Parvovirus B19 nonstructural protein transactivates the p21/WAF1 through Sp1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19861680" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29437973" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : RNA Binding Protein RBM38 Regulates Expression of the 11-Kilodalton Protein of Parvovirus B19, Which Facilitates Viral DNA Replication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289612" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The structure of human parvovirus B19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6835376" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A human parvovirus-like virus inhibits haematopoietic colony formation in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8211117" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Erythrocyte P antigen: cellular receptor for B19 parvovirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8139629" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24889255" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Parvovirus B19 VLP recognizes globoside in supported lipid bilayers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9950151" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Globoside expression within the human placenta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3330858" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Tissue distribution of H, Lewis and P antigens as shown by a panel of 18 monoclonal antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11287560" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12907437" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16076874" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20826697" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30575471" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Parvovirus B19 Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22872003" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : miRNA as activity markers in Parvo B19 associated heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2841879" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Erythema infectiosum (fifth disease) occurrence in Iowa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8098391" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Human parvovirus infection in homozygous sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1434067" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A significant age shift of the human parvovirus B19 antibody prevalence among young adults in Japan observed in a decade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3339634" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The prevalence of antibody to human parvovirus B19 in England and Wales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892405" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2539583" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Human parvovirus B19 infections in women of childbearing age and within families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3021807" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18198003" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Seroprevalence of parvovirus B19 in the German population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3016109" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2987695" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : An erythema infectiosum-like illness caused by human parvovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2993431" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Experimental parvoviral infection in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30999694" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Are Daycare Workers at a Higher Risk of Parvovirus B19 Infection? A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1846391" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Occupational risk factors for infection with parvovirus B19 among pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7522807" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2548096" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Human parvovirus B19 infection among hospital staff members after contact with infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7718826" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Human parvovirus B19 infection in healthcare workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7925671" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Parvovirus B19 outbreak on an adult ward.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7561182" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Parvovirus B19 infection in hospital workers: community or hospital acquisition?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9120238" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Nosocomial exposure to parvovirus B19: low risk of transmission to healthcare workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8572031" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9784661" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8432819" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6136645" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Transmission of serum parvovirus-like virus by clotting-factor concentrates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8652400" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547113" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Incidence of human parvovirus B19 DNA detection in blood donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17880600" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7594678" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Parvovirus B19 clearance from peripheral blood after acute infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9031493" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Human parvovirus B19 and blood products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20197722" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11009110" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Removal of parvovirus B19 from hemoglobin solution by nanofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22901944" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31647943" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Quantitative PCR evaluation of parvovirus B19 removal via nanofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31647943" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Quantitative PCR evaluation of parvovirus B19 removal via nanofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11161258" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Parvovirus B19: implications for transfusion medicine. Summary of a workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11778063" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19687508" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20663115" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Recipients potentially infected with parvovirus B19 by red blood cell products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21871924" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Caution in evaluation of removal of virus by filtration: Misinterpretation due to detection of viral genome fragments by PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27664778" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Detection of parvovirus B19 DNA in blood: Viruses or DNA remnants?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15956568" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : New DNA viruses identified in patients with acute viral infection syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17397006" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28184291" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Human parvovirus 4 'PARV4' remains elusive despite a decade of study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565125" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19691429" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11678936" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Persistent erythrovirus B19 urinary tract infection in an HIV-positive patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2541666" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Clinical manifestations of human parvovirus B19 in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14762186" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Parvovirus B19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7530397" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7594677" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2548098" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8083666" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Case report: detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9653169" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Human parvovirus B19 as a causative agent for rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7668905" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Persistence of parvovirus B19 in synovial fluid and bone marrow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27337440" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Parvovirus B19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651522" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30366357" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Evidence of Human Parvovirus B19 Infection in the Post-Mortem Brain Tissue of the Elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238210" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Placental cellular immune response in women infected with human parvovirus B19 during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11448804" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Association of parvovirus B19 with plasma cell-rich myocardial infiltrates after heart transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8794392" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Lymphoproliferative responses after infection with human parvovirus B19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7861814" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140790" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
